Isomorphic Labs, a London-based artificial intelligence-driven drug discovery company, has raised $2.1 billion in a new funding round, marking one of the larger financings in the AI healthcare sector.
The round was led by existing investor Thrive Capital and included Google Ventures, Alphabet, MGX, Temasek, and CapitalG. The company did not disclose its valuation.
Founded in 2021 as a spin-off from Google DeepMind, Isomorphic Labs is led by founder and CEO Demis Hassabis. The company said the new capital will be used to build out its drug design engine at scale and expand its underlying technology.
The deal adds to growing investor interest in companies trying to apply artificial intelligence to pharmaceutical research, as the sector faces pressure to show that AI can improve drug discovery timelines and outcomes.
The round was led by existing investor Thrive Capital and included Google Ventures, Alphabet, MGX, Temasek, and CapitalG. The company did not disclose its valuation.
Founded in 2021 as a spin-off from Google DeepMind, Isomorphic Labs is led by founder and CEO Demis Hassabis. The company said the new capital will be used to build out its drug design engine at scale and expand its underlying technology.
The deal adds to growing investor interest in companies trying to apply artificial intelligence to pharmaceutical research, as the sector faces pressure to show that AI can improve drug discovery timelines and outcomes.